Raymond James Trust’s Bio-Rad Laboratories Class A BIO Stock Holding History

Raymond James Trust’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-736	Closed	-$264K	–	1212
2023 Q3	$264K	Sell	736 -24	-3%	-$9.26K	0.01%	932
2023 Q2	$288K	Buy	760 +59	+8%	+$24K	0.01%	910
2023 Q1	$336K	Buy	+701	New	+$328K	0.01%	815
2022 Q4	–	Sell	-616	Closed	-$257K	–	1135
2022 Q3	$257K	Buy	616 +115	+23%	+$57.3K	0.01%	857
2022 Q2	$248K	Hold	501	–	–	0.01%	906
2022 Q1	$283K	Buy	501 +26	+5%	+$15.7K	0.01%	910
2021 Q4	$359K	Buy	475 +47	+11%	+$35.2K	0.01%	794
2021 Q3	$319K	Sell	428 -17	-4%	-$12.7K	0.01%	823
2021 Q2	$286K	Sell	445 -28	-6%	-$17K	0.01%	873
2021 Q1	$270K	Buy	+473	New	+$280K	0.01%	874
2018 Q4	–	Sell	-771	Closed	-$241K	–	826
2018 Q3	$241K	Buy	771 +36	+5%	+$11.2K	0.01%	730
2018 Q2	$212K	Buy	+735	New	+$203K	0.01%	759

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Raymond James Trust's BIO Position: Q4 2023 in Review

Raymond James Trust sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 736 shares — an estimated $264K sold.

Raymond James Trust first reported a position in BIO in Q2 2018 and held it in 12 quarters. The position peaked at $359K in Q4 2021. 484 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

Raymond James Trust reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
Raymond James Trust sold 736 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $264K.
Raymond James Trust first reported a position in Bio-Rad Laboratories Class A in Q2 2018 and held it in 12 quarters.
Raymond James Trust's Bio-Rad Laboratories Class A position peaked at $359K in Q4 2021.
484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Raymond James Trust's 13F filing for Q4 2023, filed 10 Jan 2024.